"The timeline for Paradigm's New Drug Application(NDA) with the US FDA remains on track."
They can't make a statement like this to the ASX if in fact they know the timeline has slipped by 6 months. They open themselves up to all sorts of problems like litigation etc.
I see your point about the underlying slippages and you have mentioned this before. But what I think has happened here, is that they have worked so hard on recruitment, that they know they can make time up on this aspect. So while there may be some slippages on the underlying dose trial etc, the overall programme is on target. The delay is also going to allow (hopefully) incorporating the DMOAD aspect in final part of trial.
A good announcement imo, another box ticked.
Ann: PAR Reports Phase 3 Clinical Trial Update, page-28
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99346 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 131244 | 5 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |